Stem Cells In IVF: Hope or Hype?

Peter Hollands
{"title":"Stem Cells In IVF: Hope or Hype?","authors":"Peter Hollands","doi":"10.19080/gjorm.2023.09.555769","DOIUrl":null,"url":null,"abstract":"Perhaps the most obvious link to IVF and stem cells is the development of human Embryonic Stem Cells (hESC) from the inner cell mass of human embryos [4]. Whilst hESC are pluripotent and therefore an excellent candidate for gamete production, very little progress has been made because of the legal, ethical, moral, and religious objections to creating hESC which requires the destruction of a viable human embryo [5]. Induced Pluripotent Stem Cells (iPSC) have a similar history when it comes to IVF. These are somatic cells (e.g., skin cells) which are ‘transformed’ into pluripotent stem cells by the introduction of various genes [6]. These iPSC are pluripotent and autologous, so they have the ability, in theory, to be able to carry out gametogenesis in patients undergoing fertility treatment [7]. The problems with the routine clinical use of iPSC in fertility treatment is the cost but most importantly ongoing safety concerns about iPSC because of the genes needed to be inserted to convert a somatic cell into a stem cell [8]. Mesenchymal stem cells (MSC) can be obtained from adipose tissue, bone marrow, the umbilical cord and even inside teeth [9]. These MSC stem cells can produce bone, connective tissue and adipose tissue and there are some data suggesting that MSC may be useful in premature ovarian failure [10]. The drawbacks of using MSC in the treatment of infertility are the cost and the standardization of MSC to ensure safety and efficacy [11]. All these stem cell types have their problems when considering their use in the treatment of infertility. It may be many years, if ever, before they come to routine clinical practice in the treatment of infertility.","PeriodicalId":92369,"journal":{"name":"Global journal of reproductive medicine","volume":"482 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global journal of reproductive medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/gjorm.2023.09.555769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Perhaps the most obvious link to IVF and stem cells is the development of human Embryonic Stem Cells (hESC) from the inner cell mass of human embryos [4]. Whilst hESC are pluripotent and therefore an excellent candidate for gamete production, very little progress has been made because of the legal, ethical, moral, and religious objections to creating hESC which requires the destruction of a viable human embryo [5]. Induced Pluripotent Stem Cells (iPSC) have a similar history when it comes to IVF. These are somatic cells (e.g., skin cells) which are ‘transformed’ into pluripotent stem cells by the introduction of various genes [6]. These iPSC are pluripotent and autologous, so they have the ability, in theory, to be able to carry out gametogenesis in patients undergoing fertility treatment [7]. The problems with the routine clinical use of iPSC in fertility treatment is the cost but most importantly ongoing safety concerns about iPSC because of the genes needed to be inserted to convert a somatic cell into a stem cell [8]. Mesenchymal stem cells (MSC) can be obtained from adipose tissue, bone marrow, the umbilical cord and even inside teeth [9]. These MSC stem cells can produce bone, connective tissue and adipose tissue and there are some data suggesting that MSC may be useful in premature ovarian failure [10]. The drawbacks of using MSC in the treatment of infertility are the cost and the standardization of MSC to ensure safety and efficacy [11]. All these stem cell types have their problems when considering their use in the treatment of infertility. It may be many years, if ever, before they come to routine clinical practice in the treatment of infertility.
体外受精干细胞:希望还是炒作?
也许与体外受精和干细胞最明显的联系是人类胚胎干细胞(hESC)从人类胚胎的内部细胞群中发育出来。虽然hESC是多能性的,因此是配子生产的绝佳候选,但由于法律、伦理、道德和宗教对创造hESC的反对,需要破坏可存活的人类胚胎,因此几乎没有取得进展。诱导多能干细胞(iPSC)在体外受精方面也有类似的历史。这些体细胞(如皮肤细胞)通过引入各种基因[6]被“转化”为多能干细胞。这些iPSC是多能性的和自体的,所以从理论上讲,它们有能力在接受生育治疗的患者中进行配子发生。在生育治疗中常规临床使用iPSC的问题是成本,但最重要的是对iPSC的持续安全担忧,因为将体细胞转化为干细胞需要插入基因。间充质干细胞(MSC)可以从脂肪组织、骨髓、脐带甚至牙齿内部获得。这些间充质干细胞可以产生骨骼、结缔组织和脂肪组织,一些数据表明间充质干细胞可能对卵巢早衰有用。使用间充质干细胞治疗不孕症的缺点是成本和标准化,以确保间充质干细胞的安全性和有效性。所有这些类型的干细胞在治疗不孕症时都有自己的问题。这可能是许多年,如果有的话,在他们进入常规临床实践治疗不孕症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信